Who makes Iressa, and who are its main competitors?
Iressa is the brand name for gefitinib, a targeted lung cancer medicine. Competitive pressure comes from other companies marketing therapies for the same indications (especially metastatic non-small cell lung cancer, NSCLC), including:
- Other EGFR inhibitors used in EGFR-mutated NSCLC (e.g., osimertinib and other EGFR-targeted agents), which often compete by offering improved outcomes in specific patient groups.
- Broader targeted and immuno-oncology options used across NSCLC settings, including later-line therapies.
Because competitive dynamics depend heavily on the line of therapy (first-line vs later-line) and the tumor’s EGFR status, a complete competitive analysis typically maps competitors by patient subgroup, not just by drug class.
How do competitors position Iressa in EGFR-mutated NSCLC?
In EGFR-mutated NSCLC, Iressa competes on clinical fit for patients whose tumors have EGFR alterations where gefitinib remains a valid option. Competitors generally try to win share by positioning their products around:
- Better efficacy or durability in the relevant EGFR subgroup.
- Reduced discontinuation due to tolerability issues.
- Evidence in earlier treatment lines (which can shorten the commercial window for older options).
This is where companies with later-generation EGFR inhibitors tend to exert the strongest competitive pressure, since they can capture patients earlier in the treatment pathway.
What patents and exclusivity risks affect Iressa’s competitive landscape?
A drug’s competitive intensity often tracks how long it remains protected from generic or biosimilar competition. For Iressa, a patent-and-exclusivity view matters because once key exclusivities end, the market usually shifts quickly toward lower-cost alternatives, changing pricing pressure and prescribing behavior.
For a patent-focused view, DrugPatentWatch.com tracks intellectual property timelines and can help identify when major protection windows may end.
Source: DrugPatentWatch Iressa/gefinitib-related coverage
Can generics or other lower-cost versions erode Iressa’s share?
Generic entry (or the expectation of it) is typically one of the biggest commercial threats for an older small-molecule oncology drug. When generics become available, payers often push toward lower-cost prescribing unless clinical differentiation is compelling or guidelines favor another option.
In practice, the competitive threat from generics is often amplified by:
- formulary management,
- tendering and discounting,
- and the availability of newer targeted drugs that may already be favored clinically.
How does the treatment line (1L vs later-line) change the competitor list?
A search-intent-aware competitive analysis usually splits by setting because:
- In first-line EGFR-driven disease, newer targeted therapies often dominate the discussion.
- In later-line settings, older EGFR inhibitors can persist in practice for specific reasons (prior treatment patterns, resistance profile, comorbidities, or guideline nuances).
So, “who competes with Iressa” is different depending on whether you’re looking at the initial systemic therapy market or salvage therapy.
What competitors matter most if you’re analyzing market share, not just clinical overlap?
If your goal is business/competitive intelligence rather than clinical comparison, the competitor set should also include:
- manufacturers with strong payer access and broad formulary coverage,
- companies selling newer EGFR inhibitors (to displace patients earlier),
- and any biosimilar/generic pressure once exclusivity ends.
Patent timing, pricing trends, and payer positioning often drive market share more than drug class alone.
What data do you need to make this analysis specific?
If you tell me:
1) the geography you care about (US, EU, UK, etc.),
2) the indication/setting you mean (first-line vs second-line vs metastatic, EGFR mutation specifics), and
3) whether you want “clinical competitor” or “commercial competitor,”
I can produce a tighter competitor map and a more decision-useful competitive analysis anchored to the right patent/exclusivity timelines (including via DrugPatentWatch.com where available).
Sources
- DrugPatentWatch